Engagement of integrin α4β1 enhances thrombopoietin-induced megakaryopoiesis

被引:31
作者
Fox, NE [1 ]
Kaushansky, K [1 ]
机构
[1] Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA
关键词
D O I
10.1016/j.exphem.2004.10.002
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. Studies in numerous adherent cell systems have indicated that engagement of integrins is required for cell survival and proliferation. Although not classically thought of as an adherent cell type, megakaryocytes in the marrow develop in juxtaposition to endothelial cells which display a number of integrin counter-receptors. Moreover, a number of other hematopoietic cell types, including stem cells and erythroid progenitors, have been shown to engage and be affected by integrin ligands. Methods. The role of beta1 integrins in thrombopoietin-mediated megakaryopoiesis was studied using both gain-of-function and loss-of-function strategies. Results. We found that pan-blockade of integrins with a relatively nonspecific disintegrin blocked TPO-induced MK growth, but that an alpha5beta1 disintegrin, and a function-blocking monoclonal antibody, failed to affect megakaryopoiesis in vitro. In contrast, a neutralizing alpha4beta1 monoclonal antibody blocked TPO-induced MK growth, and an integrin alpha4beta1 ligand, the H296 fragment of fibronectin, enhanced MK growth at all concentrations of TPO. Conclusions. These findings have important implications for thrombopoiesis in general, and potentially for the enhanced platelet production found in states of systemic inflammation and following the use of therapeutic strategies designed to block alpha4beta1 integrin engagement in states of chronic inflammation and autoimmunity. (C) 2005 International Society for Experimental Hematology. Published by Elsevier Inc.
引用
收藏
页码:94 / 99
页数:6
相关论文
共 66 条
[1]   Chemokine-mediated interaction of hematopoietic progenitors with the bone marrow vascular niche is required for thrombopoiesis [J].
Avecilla, ST ;
Hattori, K ;
Heissig, B ;
Tejada, R ;
Liao, F ;
Shido, K ;
Jin, DK ;
Dias, S ;
Zhang, F ;
Hartman, TE ;
Hackett, NR ;
Crystal, RG ;
Witte, L ;
Hicklin, DJ ;
Bohlen, P ;
Eaton, D ;
Lyden, D ;
de Sauvage, F ;
Rafii, S .
NATURE MEDICINE, 2004, 10 (01) :64-71
[2]   CHARACTERIZATION OF ADHESIVE INTERACTIONS BETWEEN HUMAN ENDOTHELIAL-CELLS AND MEGAKARYOCYTES [J].
AVRAHAM, H ;
COWLEY, S ;
CHI, SY ;
JIANG, SX ;
GROOPMAN, JE .
JOURNAL OF CLINICAL INVESTIGATION, 1993, 91 (06) :2378-2384
[3]   c-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia [J].
Ballmaier, M ;
Germeshausen, M ;
Schulze, H ;
Cherkaoui, K ;
Lang, S ;
Gaudig, A ;
Krukemeier, S ;
Eilers, M ;
Strauss, G ;
Welte, K .
BLOOD, 2001, 97 (01) :139-146
[4]   THROMBOPOIETIN (C-MPL LIGAND) ACTS SYNERGISTICALLY WITH ERYTHROPOIETIN, STEM-CELL FACTOR, AND INTERLEUKIN-11 TO ENHANCE MURINE MEGAKARYOCYTE COLONY GROWTH AND INCREASES MEGAKARYOCYTE PLOIDY IN-VITRO [J].
BROUDY, VC ;
LIN, NL ;
KAUSHANSKY, K .
BLOOD, 1995, 85 (07) :1719-1726
[5]  
CARLOS TM, 1994, BLOOD, V84, P2068
[6]  
CarverMoore K, 1996, BLOOD, V88, P803
[7]  
CHOI ES, 1995, BLOOD, V85, P402
[8]   Calcium mobilization and Rac1 activation are required for VCAM-1 (vascular cell adhesion molecule-1) stimulation of NADPH oxidase activity [J].
Cook-Mills, JM ;
Johnson, JD ;
Deem, TL ;
Ochi, A ;
Wang, L ;
Zheng, Y .
BIOCHEMICAL JOURNAL, 2004, 378 :539-547
[9]  
Cui L, 1997, J IMMUNOL, V159, P1961
[10]   Interleukin-11: Review of molecular, cell biology, and clinical use [J].
Du, XX ;
Williams, DA .
BLOOD, 1997, 89 (11) :3897-3908